CrownBio Agrees to be Acquired by JSR of Japan in $400 Million Deal
publication date: Dec 20, 2017
Crown Bioscience, a CRO with facilities in China, Taiwan, the US and Europe, will be acquired for $400 million by JSR Corporation of Japan. The offer was a 105% premium to the previous day's CrownBio stock price. With an extensive library of patient-derived xenograft (PDX) models, CrownBio offers translational programs for drug discovery and development in oncology, inflammation, cardiovascular and metabolic disease research. JSR is known as a materials sciences company, primarily for rubber-type products. It has recently expanded into life science through acquisitions. More details....
Stock Symbol: (TPEX: 6554)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.